Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 1,193 full-time employees. The company went IPO on 2015-06-25. The firm's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The firm's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The firm's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The firm's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
¿Cuál es el ratio P/E de Lantheus Holdings Inc (LNTH)?
El ratio P/E de Lantheus Holdings Inc es 21.117
¿Qué tal es el rendimiento del precio de la acción LNTH?
El precio actual de LNTH es de $83.27, ha disminuido un 0.99% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Lantheus Holdings Inc?
Lantheus Holdings Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Lantheus Holdings Inc?
La capitalización bursátil actual de Lantheus Holdings Inc es $5.4B
¿Es Lantheus Holdings Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 15 analistas han realizado calificaciones de análisis para Lantheus Holdings Inc, incluyendo 4 fuerte compra, 12 compra, 3 mantener, 0 venta, y 4 fuerte venta